Gökhan Aksan1, Sinan İnci2, Gökay Nar2, Korhan Soylu3, Ömer Gedikli4, Serkan Yüksel3, Metin Özdemir5, Rukiye Nar6, Murat Meriç3, Mahmut Şahin3. 1. Department of Cardiology, Gazi State Hospital Samsun, Turkey. 2. Departmant of Cardiology, Aksaray State Hospital Aksaray, Turkey. 3. Department of Cardiology, Faculty of Medicine, Ondokuz Mayis University Samsun, Turkey. 4. Departmant of Cardiology, Artvin State Hospital Artvin, Turkey. 5. Department of Microbiology, Gazi State Hospital Samsun, Turkey. 6. Departmant of Biochemistry, Aksaray State Hospital Aksaray, Turkey.
Abstract
OBJECTIVES: The newly identified adipokine chemerin has been shown to be associated with the components of MetS, inflammation and insulin resistance. In this study, the relationship between serum chemerin levels and the presence and severity of coronary artery disease (CAD) was evaluated in patients with MetS. METHODS: The study population consisted of 84 MetS patients (43 patients with CAD and 41 without CAD), who had coronary angiography for suspected coronary artery disease, and 46 healthy individuals as a control group. Angiographic CAD was defined as ≥ 50% luminal diameter stenosis of at least one major epicardial coronary artery. The severity of CAD was determined by the Gensini score. Serum chemerin levels were measured with enzyme linked immunosorbent assay (ELISA). RESULTS: Serum chemerin levels were significantly higher in patients with MetS (n=84) than those in the control group (120.47±25.32 vs. 90.4±11.4 ng/ml P < 0.001). In addition, MetS patients with CAD had higher chemerin levels than MetS patients without CAD (128.7±26.6 vs. 115.7±15.2 ng/ml, P < 0.001). Serum chemerin levels had a significant positive correlation with the Gensini score (r=0.58, P < 0.001). Multivariate logistic regression demonstrated that serum high-density lipoprotein cholesterol (HDL-C) and chemerin levels were significant and independent predictors for determining the presence of angiographic CAD (OR=1.009, 95% CI: 0.972-1.057; P=0.003 and OR=0.925, 95% CI: 0.896-0.922; P < 0.001, respectively). CONCLUSION: This study demonstrated that in patients with MetS, chemerin levels were higher in patients with CAD than patients without CAD and also showed a significant positive correlation with CAD severity.
OBJECTIVES: The newly identified adipokine chemerin has been shown to be associated with the components of MetS, inflammation and insulin resistance. In this study, the relationship between serum chemerin levels and the presence and severity of coronary artery disease (CAD) was evaluated in patients with MetS. METHODS: The study population consisted of 84 MetS patients (43 patients with CAD and 41 without CAD), who had coronary angiography for suspected coronary artery disease, and 46 healthy individuals as a control group. Angiographic CAD was defined as ≥ 50% luminal diameter stenosis of at least one major epicardial coronary artery. The severity of CAD was determined by the Gensini score. Serum chemerin levels were measured with enzyme linked immunosorbent assay (ELISA). RESULTS: Serum chemerin levels were significantly higher in patients with MetS (n=84) than those in the control group (120.47±25.32 vs. 90.4±11.4 ng/ml P < 0.001). In addition, MetS patients with CAD had higher chemerin levels than MetS patients without CAD (128.7±26.6 vs. 115.7±15.2 ng/ml, P < 0.001). Serum chemerin levels had a significant positive correlation with the Gensini score (r=0.58, P < 0.001). Multivariate logistic regression demonstrated that serum high-density lipoprotein cholesterol (HDL-C) and chemerin levels were significant and independent predictors for determining the presence of angiographic CAD (OR=1.009, 95% CI: 0.972-1.057; P=0.003 and OR=0.925, 95% CI: 0.896-0.922; P < 0.001, respectively). CONCLUSION: This study demonstrated that in patients with MetS, chemerin levels were higher in patients with CAD than patients without CAD and also showed a significant positive correlation with CAD severity.
Authors: Sofia G Spiroglou; Christos G Kostopoulos; John N Varakis; Helen H Papadaki Journal: J Atheroscler Thromb Date: 2010-02-10 Impact factor: 4.928
Authors: Y Nakamura; K Shimada; D Fukuda; Y Shimada; S Ehara; M Hirose; T Kataoka; K Kamimori; S Shimodozono; Y Kobayashi; M Yoshiyama; K Takeuchi; J Yoshikawa Journal: Heart Date: 2004-05 Impact factor: 5.994
Authors: Erik Ingelsson; Johan Sundström; Håkan Melhus; Karl Michaëlsson; Christian Berne; Ramachandran S Vasan; Ulf Risérus; Rune Blomhoff; Lars Lind; Johan Arnlöv Journal: Atherosclerosis Date: 2009-03-11 Impact factor: 5.162
Authors: Christos G Kostopoulos; Sofia G Spiroglou; John N Varakis; Efstratios Apostolakis; Helen H Papadaki Journal: BMC Cardiovasc Disord Date: 2014-04-30 Impact factor: 2.298